


40. (Twice Amended) The method of claim 27, wherein the CpG oligonucleotide has a sequence including at least the following formula:



wherein X₁, X₂, X₃, and X₄ are nucleotides, N is a nucleic acid sequence composed of from about 0-25 nucleotides.

49. (Twice Amended) The method of claim 42, wherein the CpG oligonucleotide has a sequence including at least the following formula:



wherein X₁, X₂, X₃, and X₄ are nucleotides, N is a nucleic acid sequence composed of from about 0-25 nucleotides.

62. (Twice Amended) The method of claim 51, wherein the CpG oligonucleotide has a sequence including at least the following formula:



wherein X₁, X₂, X₃, and X₄ are nucleotides, N is a nucleic acid sequence composed of from about 0-25 nucleotides.

68. (Amended) The method of claim 66, wherein the CpG oligonucleotide has a sequence including at least the following formula:



wherein X₁, X₂, X₃, and X₄ are nucleotides, N is a nucleic acid sequence composed of from about 0-25 nucleotides.

Remarks

Claims 1-77 are pending. Claims 11, 40, 49, 62, and 68 have been rewritten as required by the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures. No claims have been cancelled. No new claims are presented. The specification has been amended to associate each unique nucleotide sequence with a unique SEQ ID NO. The specification has also been amended to correct